Blog

Xiuning Le: Excited about our upcoming presentations at ASCO2025

Xiuning Le/X

May 27, 2025, 12:04

Xiuning Le: Excited about our upcoming presentations at ASCO2025

Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on LinkedIn:

“Excited about our upcoming presentations at ASCO2025. Each study represents a meaningful step forward to improve outcomes for cancer pts.

For HER2 mutation NSCLC:

SOHO-01 Herbert Loong, Safety and efficacy of BAY88 (sevabernib) in prior treated and treatment-naïve HER2 NSCLC Dominik Ruettinger, Christian Rommel, Paolo Grassi, Abdelali (Ali) Majdi.

SOHO-02 (Trial-in-progress) global randomized phase 3 study for sevabertinib (BAY88) vs. SOC in HER2-acivating mutation NSCLC pts Sébastien Denis, Nicoletta Brega, Vadim Bernard-Gauthier, Joan Agretelis with Dr. Antonio Passaro.

HEROEX1 trial for NVL-330 (Trial-in-progress) a novel CNS-penetrating HER2 TKI in HER2-altered NSCLC Viola Zhu, Vivek Upadhyay with Drs. Jonathan Riess, Shirish Gadgeel, Steven Margossian.

For EGFR mutation NSCLC:

SOLARA trial for BN-30643 (Trial-in-progress) a highly potent EGFR OMNI inhibitor FIH study in NSCLC J. Jean Cui, Geoff Oxnard with Dr. Hidehito Horinouchi.

For METex14 skipping NSCLC:

Venametkib in METex14 NSCLC: ORR 43% (n=37 pts), DCR 97% with 1L PFS 15.7 months. Peripheral edema rate only at 15%, open opportunities to combine.

It’s a privilege to work with such talented collaborators and institutions dedicated to advancing translational science into clinical impact.

If you’re attending ASCO25, please stop by or reach out to connect — I’d love to discuss the science and hear your insights.”

Xiuning Le previewed a series of clinical trial presentations for ASCO 2025 focused on HER2-mutated, EGFR-mutated, and METex14-skipping NSCLC. The highlighted studies include early-phase and ongoing trials evaluating sevabernib, NVL-330, BN-30643, and venametkib, reflecting continued progress in targeted therapy and translational science.

More posts featuring Xiuning Le.

Abdelali (Ali) Majdi Antonio Passaro ASCO2025 BAY88 BN-30643 cancer Christian Rommel Dominik Ruettinger EGFR-mutation fight against cancer Geoff Oxnard Global fight against cancer HER2 Herbert Loong HEROEX1 trial Hidehito Horinouchi J. Jean Cui Joan Agretelis Jonathan Riess METex14 Nicoletta Brega Nirmal Rajasekaran NSCLC NVL-330 OncoDaily Oncology ORR Paolo Grassi Sébastien Denis sevabernib Shirish Gadgeel SOHO-01 SOHO-02 SOLARA trial Steven Margossian Vadim Bernard-Gauthier Venametkib Viola Zhu Vivek Upadhyay Xiuning Le

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action

King Hussein Cancer Research Award: Don’t Miss Your Chance to Apply